Immune Systems Advisor

As rates of infection with influenza and RSV rose in fall/winter 2022, FLCCC adapted the I-PREVENT protocol to include prevention against these viruses. The interventions recommended are likely to reduce the risk and severity of infection with COVID-19, influenza, and RSV infections as well as the common cold. It should be noted that the medications included in the I-PREVENT protocol are inexpensive, safe, and widely available. This protocol includes a section for pre-exposure (long-term) as well as a post-exposure (acute, short-term). ( Independent Medical Alliance ) About this Protocol The information in this document is FLCCC recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications a...

An Approach to Post-Vaccine Cardiovascular and Cancer Care There is very limited data on the clinical features, pathogenetic mechanisms, and pathological findings of patients who have had delayed complications related to the COVID-19 vaccine. In addition, there is no published guidance on how to avoid these complications. This guidance is, therefore, based on our assessment of the likely pathogenic mechanisms underlying these delayed complications (spike protein-related disease) and the limited available autopsy data. Post-Vaccine Cardiovascular Events and Cancer Most serious adverse events following vaccination occur in the two weeks immediately following a dose of the vaccine. However, evolving data suggest that some patients who otherwise had no adverse events from the vaccine appear to have delayed acute cardiac events (often leading to sudden death). This appears to peak between 4 to 6 months after the vaccine but may extend for at least one year. There has also been evidence of a...